Physician profile
Gregory A Strunk
NPI 1740486281
$2,342.54
in general payments reported to CMS, 2019-2025
24 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $132 · 2021: $464 · 2022: $669 · 2023: $299 · 2024: $210 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $659.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $400.52 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $340.22 | 2019-2025 | Zepbound, Mounjaro, Trulicity |
| Sanofi-Aventis U.S. LLC | $291.16 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $152.57 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $149.64 | 2019 | |
| Glaxosmithkline, LLC. | $133.79 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Paratek Pharmaceuticals, INC. | $124.38 | 2022-2025 | Nuzyra, Xhance |
| Astellas Pharma US INC | $121.26 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $110.22 | 2021-2023 | Livalo, Seglentis |
| Abbvie INC. | $95.27 | 2022-2024 | Mavyret, Qulipta, Ubrelvy |
| Pfizer INC. | $62.51 | 2020-2024 | |
| Biohaven Pharmaceuticals, INC. | $58.67 | 2021 | |
| Genentech USA, INC. | $55.06 | 2020-2022 | |
| Sanofi Pasteur INC. | $32.92 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $31.26 | 2019-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $31.02 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $30.76 | 2020-2022 | |
| Boston Scientific Corporation | $29.46 | 2022 | |
| Exact Sciences Corporation | $19.86 | 2024 | Cologuard Collection Kit |
| Averitas Pharma INC. | $17.95 | 2025 | Qutenza |
| Amarin Pharma, INC. | $13.96 | 2022 | |
| Corcept Therapeutics | $13.68 | 2025 | Korlym |
| Medtronic, INC. | $13.55 | 2024 | Minimed 780g |
| Bayer Healthcare Pharmaceuticals INC. | $12.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Strunk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.